
Elahare announced the new Healthcare Common Procedure Coding System (HCPCS) C-code for ElahereTM (mirvetuximab soravtansine-gynx), issued by the Centers for Medicare & Medicaid Services (CMS). The code C9146 is effective April 1, 2023 for mirvetuximab soravtansine-gynx injection of 1mg and may be used on claims billed under the hospital Outpatient Prospective Payment System.
For more information visit the Elahare website.
Posted 3/23/2023

Each year, the NCCN State Oncology Society Forum is thoughtfully organized to foster meaningful collaboration and forge common bonds to advance dignity and fair access to cancer care. In this blog, Sean T. McCarson shares key insights from stakeholders across the oncology policy landscape at this year's meeting.

The latest issue of Oncology Issues features key insights from the inaugural ACCC Leadership Summit, strategies to adjust to rising patient volumes and workforce strain, advanced practice leadership models, and more.

In the third in a series of multidisciplinary consensus-building roundtables, ACCC and its partners explored ways to bridge the gap between community oncology programs and authorized treatment centers offering CAR T for patients with multiple myeloma.

In a recent conversation with ACCC, Kevan Simms, MBA, PMP, Assistant Vice President of Precision Medicine at Ochsner Health, shared how his organization is building a scalable stewardship model that not only improves current oncology care but also prepares for the future.
